Cystic Fibrosis: Emerging Understanding and Therapies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30312551.
- Also identified by DOI 10.1146/annurev-med-112717-094536.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cystic fibrosis (CF) is the most common life-limiting genetic disease in Caucasian patients. Continued advances have led to improved survival, and adults with CF now outnumber children. As our understanding of the disease improves, new therapies have emerged that improve the basic defect, enabling patient-specific treatment and improved outcomes. However, recurrent exacerbations continue to lead to morbidity and mortality, and new pathogens have been identified that may lead to worse outcomes. In addition, new complications, such as CF-related diabetes and increased risk of gastrointestinal cancers, are creating new challenges in management. For patients with end-stage disease, lung transplantation has remained one of the few treatment options, but challenges in identifying the most appropriate patients remain.
Medical subject headings
- Aminophenols
- Cystic Fibrosis
- Cystic Fibrosis Transmembrane Conductance Regulator
- Disease Management
- Quinolones